Mads Israelsen

2.5k total citations · 3 hit papers
43 papers, 907 citations indexed

About

Mads Israelsen is a scholar working on Epidemiology, Hepatology and Pathology and Forensic Medicine. According to data from OpenAlex, Mads Israelsen has authored 43 papers receiving a total of 907 indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Epidemiology, 25 papers in Hepatology and 21 papers in Pathology and Forensic Medicine. Recurrent topics in Mads Israelsen's work include Liver Disease Diagnosis and Treatment (39 papers), Liver Disease and Transplantation (24 papers) and Alcohol Consumption and Health Effects (21 papers). Mads Israelsen is often cited by papers focused on Liver Disease Diagnosis and Treatment (39 papers), Liver Disease and Transplantation (24 papers) and Alcohol Consumption and Health Effects (21 papers). Mads Israelsen collaborates with scholars based in Denmark, Spain and United Kingdom. Mads Israelsen's co-authors include Aleksander Krag, Maja Thiele, Lise Lotte Gluud, Nikolaj Torp, Emmanuel Tsochatzis, Stine Johansen, Sven Francque, Camilla Dalby Hansen, Annette Dam Fialla and Ole Hamberg and has published in prestigious journals such as The Lancet, Hepatology and Cochrane Database of Systematic Reviews.

In The Last Decade

Mads Israelsen

36 papers receiving 891 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease

2023 116 citations Maria Kjærgaard, Katrine Prier Lindvig et al. Journal of Hepatology profile →
Steatotic liver disease

2024 95 citations Mads Israelsen, Emmanuel Tsochatzis et al. profile →
Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study

2024 75 citations Mads Israelsen, Nikolaj Torp et al. The Lancet. Gastroenterology & hepatology profile →

Peers

Mads Israelsen

EPIDE

HEPAT

PFM

EDM

SURGE

Alessandra Marrazzo Italy

Lorenz Balcar Austria

Muhammad Ali Khan United States

Kuei‐Chuan Lee Taiwan

M J Farahvash Iran

Fabio Mecca Italy

You Ming Li China

Fátima Higuera-de la Tijera Mexico

Tsubasa Tsutsumi Japan

Leslie Y. Kam United States

Alessandra Marrazzo Italy

Mads Israelsen

667 ×0.9

EPIDE

263 ×0.6

HEPAT

123 ×0.4

PFM

301 ×1.4

EDM

92 ×0.6

SURGE

Citations per year, relative to Mads Israelsen Mads Israelsen (= 1×) peers Alessandra Marrazzo

Countries citing papers authored by Mads Israelsen

Since Specialization

Citations

This map shows the geographic impact of Mads Israelsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mads Israelsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mads Israelsen more than expected).

Fields of papers citing papers by Mads Israelsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mads Israelsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mads Israelsen. The network helps show where Mads Israelsen may publish in the future.

Co-authorship network of co-authors of Mads Israelsen

This figure shows the co-authorship network connecting the top 25 collaborators of Mads Israelsen. A scholar is included among the top collaborators of Mads Israelsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mads Israelsen. Mads Israelsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hansen, Camilla Dalby, Lorenz Balcar, K. Bech, et al.. (2025). PNPLA3 and TM6SF2 exacerbate the impact of alcohol and metabolic dysfunction on liver fibrosis. JHEP Reports. 8(1). 101649–101649.

Torp, Nikolaj, Louise China, Mads Israelsen, et al.. (2025). Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE. Annals of Hepatology. 30(2). 101941–101941. 1 indexed citations

Krag, Aleksander, Nikolaj Torp, Zobair M. Younossi, & Mads Israelsen. (2025). Reporting discrepancy of alcohol intake affecting estimated prevalence of MetALD and ALD. The Lancet. Gastroenterology & hepatology. 10(4). 282–284. 9 indexed citations

Torp, Nikolaj, Mads Israelsen, Maja Thiele, Mary E. Rinella, & Aleksander Krag. (2025). Phosphatidylethanol in steatotic liver disease. Journal of Hepatology. 83(5). 1189–1203. 3 indexed citations

Israelsen, Mads, Katrine Holtz Thorhauge, Peter Andersen, et al.. (2025). Steatotic Liver Disease Classification Is Dynamic, Affecting Clinical Trial Eligibility and Subclass-Specific Treatments. Clinical Gastroenterology and Hepatology. 23(13). 2509–2518. 6 indexed citations

Torp, Nikolaj, Mads Israelsen, Minneke J. Coenraad, et al.. (2024). Personalised human albumin in patients with cirrhosis and ascites: design and rationale for the ALB-TRIAL - a randomised clinical biomarker validation trial. BMJ Open. 14(2). e079309–e079309. 6 indexed citations

Thorhauge, Katrine Holtz, Georg Semmler, Stine Johansen, et al.. (2024). Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease. Journal of Hepatology. 81(1). 23–32. 20 indexed citations

Houben, Tom, Albert V. Bitorina, Dennis M. Meesters, et al.. (2024). Plasma cathepsin D as an early indicator of alcohol-related liver disease. JHEP Reports. 6(9). 101117–101117.

Torp, Nikolaj, Mads Israelsen, & Aleksander Krag. (2024). The steatotic liver disease burden paradox: unravelling the key role of alcohol. Nature Reviews Gastroenterology & Hepatology. 22(4). 281–292. 13 indexed citations

10.

Lindvig, Katrine Prier, Sören Möller, Katrine Holtz Thorhauge, et al.. (2024). FRI-045 Superior prognostic accuracy of the LiverPRO score versus FIB-4 in predicting liver-related events in a cohort of 457, 152 individuals. Journal of Hepatology. 80. S205–S206. 1 indexed citations

11.

Stankevič, Evelina, Mads Israelsen, Helene Bæk Juel, et al.. (2023). Binge drinking episode causes acute, specific alterations in systemic and hepatic inflammation‐related markers. Liver International. 43(12). 2680–2691. 15 indexed citations

12.

Johansen, Stine, Mads Israelsen, Ida Falk Villesen, et al.. (2023). Validation of scores of PRO‐C3 to predict liver‐related events in alcohol‐related liver disease. Liver International. 43(7). 1486–1496. 8 indexed citations

13.

Thiele, Maja, Stine Johansen, Mads Israelsen, et al.. (2023). Noninvasive assessment of hepatic decompensation. Hepatology. 81(3). 1019–1037. 14 indexed citations

14.

Kjærgaard, Maria, Katrine Prier Lindvig, Katrine Holtz Thorhauge, et al.. (2023). Screening for Fibrosis Promotes Lifestyle Changes: A Prospective Cohort Study in 4796 Individuals. Clinical Gastroenterology and Hepatology. 22(5). 1037–1047.e9. 28 indexed citations

15.

Kjærgaard, Maria, Katrine Prier Lindvig, Katrine Holtz Thorhauge, et al.. (2023). Using the ELF test, FIB-4 and NAFLD fibrosis score to screen the population for liver disease. Journal of Hepatology. 79(2). 277–286. 116 indexed citations breakdown →

16.

Torp, Nikolaj, Mads Israelsen, Mette Juul Nielsen, et al.. (2021). Binge drinking induces an acute burst of markers of hepatic fibrogenesis (PRO‐C3). Liver International. 42(1). 92–101. 15 indexed citations

17.

Torp, Nikolaj, Mads Israelsen, Bjørn Stæhr Madsen, et al.. (2021). Level of MFAP4 in ascites independently predicts 1-year transplant-free survival in patients with cirrhosis. JHEP Reports. 3(3). 100287–100287. 4 indexed citations

18.

Israelsen, Mads, Andrew Hall, Claudia Covelli, et al.. (2021). Collagen proportionate area predicts long-term mortality in patients with alcoholic hepatitis. Digestive and Liver Disease. 54(5). 663–668. 4 indexed citations

19.

Israelsen, Mads, Helene Bæk Juel, Sönke Detlefsen, et al.. (2020). Metabolic and Genetic Risk Factors Are the Strongest Predictors of Severity of Alcohol-Related Liver Fibrosis. Clinical Gastroenterology and Hepatology. 20(8). 1784–1794.e9. 57 indexed citations

20.

Madsen, Bjørn Stæhr, Jonel Trebicka, Maja Thiele, et al.. (2018). Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial. Trials. 19(1). 143–143. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact